TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: On Open-Label Study in Participants With Systemic Lupus Erythematosus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have completed 52 weeks of treatment in core studies (NCT01196091) (NCT01205438)~* Given written informed consent~* Test negative for pregnancy at the time of enrollment~* Agree to use a reliable method of birth control~Exclusion Criteria:~* Unwilling to comply with study procedures~* Any condition that renders the participants unable to understand the nature and scope and possible consequences of the study~* Any condition that in the opinion of the investigator poses an unacceptable risk to the participants if study drug would be administered

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LY 2127399 Q2W (Type: EXPERIMENTAL): If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at week 0, followed by 1 SC injection of 120 mg LY2127399 every 2 weeks (Q2W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at Week 0, followed by 1 SC injection of 120 mg LY2127399 Q2W for 216 weeks.
- LY2127399 Q4W (Type: EXPERIMENTAL): If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at Week 0, followed by 1 SC injection of 120 mg LY2127399 every 4 weeks (Q4W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at week 0, followed by 1 SC injection of 120 mg LY2127399 Q4W for 216 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pain in Complex Regional Pain Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* CRPS according to existing diagnostic criteria~* Numeric Rating Scale (NRS) pain \>4~Exclusion Criteria:~* Prior use of TENS for the past 6 months~* Active inflammatory conditions~* Pacemaker~* Comorbid disease that could cause neuropathic pain such as diabetic neuropathy~* Significant cognitive deficits~* Chronic pain syndrome (e.g. fibromyalgia, phantom pain, rheumatoid arthritis)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group MED (Type: NO_INTERVENTION): A group of participants that receives treatment as usual that consists of medicinal treatment, prescribed by a specialist doctor (Carsten Kock-Jensen, MD) from the CRPS clinic and will be monitored using patients' medicinal records.
- Group TENS (Type: EXPERIMENTAL): A group of participants that receives transcutaneous electrical nerve stimulation (TENS) which is an inexpensive, noninvasive and safe treatment for pain.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mild Valvar Pulmonary Stenosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Children's Healthcare of Atlanta medical charts 1984 to 2003 diagnosed with mild valvar pulmonary stenosis Patients less than or equal to two years of age~Exclusion Criteria:~* Those who do no meet inclusion criteria

- Gender: ALL
- Minimum Age: None
- Maximum Age: 2 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>/= 15 years.~2. Previously untreated ALL, Burkitt's lymphoma, or lymphoblastic leukemia receiving induction chemotherapy with hyper-CVAD or variants of the hyper-CVAD regimen.~3. Random serum glucose \>/= 180 mg/dL detected during the first 2 cycles of chemotherapy and confirmed with a second measurement.~Exclusion Criteria:~1. History of Type I diabetes mellitus.~2. Pregnancy or breast feeding.~3. Allergy to insulin or insulin products.~4. On-going treatment of steroid-induced hyperglycemia by an endocrinologist and/or general internist.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conventional Care (Type: NO_INTERVENTION): Control Group: Conventional care using blood sugar management with regular human insulin.
- Intensive Insulin (Type: OTHER): Intervention Group: Intense blood sugar management with Insulin Aspart + Insulin Glargine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Oral Penicillin and Penicillin Levels in Venous Umbilical Cord Blood

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* pregnant women admitted for delivery or for induction of labor~* singleton pregnancy~* 18 years old or older~* beyond 36 weeks gestation~* able to comprehend study and give informed consent~Exclusion Criteria:~* known history of beta-lactam antibiotic allergy~* impaired renal function~* multiple gestation~* current use of antibiotics~* plan to bank cord blood after delivery

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Oral Penicillin (Type: EXPERIMENTAL): 2 grams of oral penicillin V given within 4 hours of delivery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Double Blind Controlled Trial Comparing a Blind Sciatic Nerve Block in the Popliteal Fossa to Intravenous Morphine for Traumatic Severe Acute Pain in the Prehospital Setting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Severe pain (VAS \> or = 60mm); injuries of the leg, ankle or foot~Exclusion Criteria:~* Hypersensitivity to student agents~* Local infection~* Nerve or vascular pathology in the affected limb, coagulation pathology,~* Chronic use of opoids, use of opoids within 6 hours~* Drug addiction~* Pregnancy~* Systolic blood pressure less than 90 mmHg~* Respiratory rate less than 16 per minute~* Glasgow coma scale \< 14.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Blind block with mepivacaine (Type: EXPERIMENTAL): Blind block with mepivacaine and intravenous morphine
- Morphine (Type: ACTIVE_COMPARATOR): Intravenous Morphine and placebo blind block

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Peritoneal Nebulization of Ropivacaine for Pain Control After Laparoscopic Colectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females and Males 18-80 years old~* ASA Score I (American Society of Anesthesiologists classification : a normal healthy patient.~* ASA Score II (American Society of Anesthesiologists classification): A patient with mild systemic disease~* ASA Score III (American Society of Anesthesiologists classification): A patient with severe systemic disease~* Patients scheduled for oncological laparoscopic colectomy~* Patients who do not use opioids analgesic drugs before surgery~* Patients without cognitive impairment or mental retardation~Exclusion Criteria:~* Females and Males under 18 or over 80~* ASA Score IV (American Society of Anesthesiologists classification): A patient with severe systemic disease that is a constant threat to life~* ASA Score V (American Society of Anesthesiologists classification): A moribund patient who is not expected to survive without the operation~* Emergency/urgency surgery~* Postoperative admission in an intensive care unit with sedation or ventilatory assistance~* Cognitive impairment or mental retardation~* Use of opiods before surgery~* Progressive degenerative diseases of the CNS~* Convulsions or chronic therapy with antiepileptic drugs~* Severe hepatic or renal impairment~* Allergy to one of the specific drugs under study~* Acute infection or inflammatory chronic disease~* Alcohol or drug addiction~* Any kind of communication problem~* Neurologic or psychiatric disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ropivacaine 150 mg (Type: EXPERIMENTAL): Nebulization of Ropivacaine 150 mg in the peritoneal cavity with the Aeroneb Pro system
- Saline 15 ml (Type: PLACEBO_COMPARATOR): Nebulization of Saline 15 ml in the peritoneal cavity with the Aeroneb Pro system

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Endometrial Rejuvenation Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients planning to undergo a frozen-thawed embryo transfer cycle using a single euploid blastocyst.~2. Patients who have previously undergone at least 2 unsuccessful frozen-thawed embryo transfer cycles, defined as failure to achieve a clinical pregnancy (visualization of intrauterine gestational sac on ultrasound) or a cancelled embryo transfer cycle due to inadequate endometrial thickness.~3. Patients with a diagnosis of thin endometrial lining (less than 6 mm maximum thickness) during at least one prior unsuccessful embryo transfer cycle.~4. Initiation of the most recent unsuccessful frozen-thawed embryo transfer cycle with a thin endometrial lining must have occurred after January 1, 2017.~Exclusion Criteria:~1. Fewer than 2 prior unsuccessful frozen-thawed embryo transfer cycles.~2. Most recent unsuccessful frozen-thawed embryo transfer prior to January 1, 2017.~3. No euploid embryos available for transfer.~4. Mullerian anomalies, excluding arcuate uterus~5. Submucosal fibroids~6. History of uterine surgery, excluding polypectomy, D\&C, and Cesarean section~7. Communicating hydrosalpinx without plans for surgical correction prior to study enrollment.~8. Failure of patient to agree to enrollment in study with written consent.~9. History of drug sensitivity or adverse reaction to AMD3100 (plerixafor).~10. Pregnancy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: PLACEBO_COMPARATOR): Patients in this arm will not receive the study drug. A placebo of normal saline will be injected subcutaneously and the D\&C procedure will be completed.
- Intervention (Type: EXPERIMENTAL): Patients in this arm will receive a dose of the study drug, AMD3100, injected subcutaneously and the D\&C procedure will be completed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Vitamin D as add-on Therapy for Vitamin D Insufficient Patients With Severe Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients, age ≥ 18 years~* A pulmonary specialist documented diagnosis of severe asthma according to the Global Initiative for Asthma and the German Asthma Network (GAN, www.german-asthma-net.de)~* Treatment with long-acting β2-agonists (LABA) and inhaled corticosteroids (ICS) at a dose of at least 1000 µg beclomethasone (or equivalent) per day, - chronic oral corticosteroid (OCS) use is allowed Stable asthma medication for ≥1 month prior to screening (≥4 months for omalizumab)~* Asthma Control Questionnaire (ACQ-5) score ≥ 1.5~* Vitamin D insufficiency as defined by a serum vitamin D concentration of \< 30 ng/ml but ≥ 10 ng/ml at screening~Exclusion Criteria:~* Patients on vitamin D substitution~* Current smokers or ex-smokers with a smoking history of more than 10 pack-years~* Pregnant or nursing women or women who intend to become pregnant during the study~* Known impaired renal function (GFR \< 30 ml/min) and history of physician-diagnosed nephrolithiasis~* Use of other investigational drugs during the study or within 30 days of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vitamin D3 (Type: EXPERIMENTAL): Initial single dose 100000 IU, beginning from the second day 4000 IU/day for 24 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Amount of Placebo capsules corresponding to initial single dose of Vitamin D3, beginning from the second day amount of capsules corresponding to daily dose of Vitamin D for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: BREADS: Breast Adjuvant Diet Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed breast cancer~* Planning to start adjuvant hormonal therapy using an aromatase inhibitor or has started adjuvant hormonal therapy using an aromatase inhibitor~* Able to read, write, and understand English~* BMI ≥ 24 kg/m2~* Age ≥ 18 years~* ER and/or PR positive (defined as having ≥ 1% staining for ER and/or PR on IHC)~* Post-menopausal~  * The absence of menstrual cycles in women who have not undergone hysterectomy for at least 12 months preceding cancer diagnosis OR~ * History of a bilateral oophorectomy OR~ * History of a hysterectomy and age \>55 OR~ * No menses for \<1 year with FSh and estradiol levels in postmenopausal range according to institutional standards~* ECOG Performance Status 0 or 1~* Female~* Written informed consent obtained from subject and ability for subject to comply with requirements of the study~Exclusion Criteria:~* Use of hormonal therapy other than aromatase inhibitors~* History of other malignancy within the past 5 years, except for malignancies with a \> 95% likelihood of cure (e.g. thyroid cancer, non-melanoma skin cancer)~* Already consuming a severe carbohydrate restricted (\<20 g carbohydrates per day) diet or vegetarian diet~* Currently on or plans to start chemotherapy (HER2/neu targeted therapy okay)~* Medical comorbidities that in the opinion of the investigator limits the patient's ability to complete the study~* Symptomatic metastases (Metastases allowed if asymptomatic)~* Current use of appetite suppressant medications~* Current use of any weight loss medications including herbal weight loss supplements or if patients are enrolled in a diet/weight loss program

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dietary intervention (Type: EXPERIMENTAL): Carbohydrate restricted dietary intervention (\<20 g carbohydrates/day) + standard of care aromatase inhibitors
- No dietary intervention (Type: ACTIVE_COMPARATOR): Standard of care aromatase inhibitors

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Archimedes™ System for Transparenchymal Nodule Access

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 21-75 years at screening~2. Highly suspicious SPN, defined as distinct nodule with a diameter of ≥8mm in its largest dimension~3. No known endobronchial tumor~4. Tumor located anywhere in parenchymal tissue \>1 cm from pleura and accessible bronchoscopically through a POE.~5. Willing to participate in all aspects of study protocol for duration of study~6. Able to understand study requirements~7. Signs study-related informed consent document~Exclusion Criteria:~1. Any contraindication to bronchoscopy, for example:~   * Untreatable life-threatening arrhythmias~  * Inability to adequately oxygenate the patient during the procedure~  * Acute respiratory failure with hypercapnia (unless the patient is intubated and ventilated)~  * Recent myocardial infarction~  * Previously diagnosed high-grade tracheal obstruction~  * Uncorrectable coagulopathy~2. Known coagulopathy~3. Platelet dysfunction or platelet count \< 100 x 103 cells/mm3~4. History of major bleeding with bronchoscopy~5. Suspected pulmonary hypertension: additional testing required, such as echocardiogram~6. Moderate-to-severe pulmonary fibrosis~7. Severe emphysema or COPD: additional testing and PI consent is required~8. Bullae \>5 cm located in vicinity of target SPN~9. Any other severe or life-threatening comorbidity that could increase the risk of bronchoscopic biopsy or ATV tunneling, for example:~   * ASA class \> 3~  * \> stage 3 heart failure~  * severe cachexia~  * severe respiratory insufficiency or hypoxia~10. Ongoing systemic infection~11. Contraindication to general anesthesia~12. Inability to stop anticoagulants (e.g., heparin, Warfarin) or antiplatelet agents (e.g. aspirin, clopidogrel) prior to procedure~13. Participation in any other study in last 30 days~14. Prior thoracic surgery on the same side of the lung as the SPN.~15. Breastfeeding women or females of childbearing potential with a positive pregnancy test prior to the procedure or the intent to become pregnant during the study.~16. Life expectancy of less than one year.~17. Scheduled for lung surgery within 72hrs post-scheduled diagnostic bronchoscopy~18. Pregnancy

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Navigation and tissue sampling (Type: EXPERIMENTAL): Guided bronchoscopic navigation and lung tissue sampling using the Archimedes System

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Effect of Online Mental Health Literacy Training

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* student-athletes~Exclusion Criteria:~* non student-athletes

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intervention (Type: EXPERIMENTAL): Receives the supporting student-athlete mental wellness module
- Waitlist (Type: NO_INTERVENTION): Receives no intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues